BioNTech SE (BNTX) Cash from Operations (2018 - 2026)
BioNTech SE (BNTX) posted Cash from Operations of 360271467.8 for Q4 2025, down 60.53% sequentially from 912681309.82 in Q3 2025, and up 172.77% YoY from 132078692.22 in Q4 2024.
Powered by 
Analysis
BioNTech SE (BNTX) Cash from Operations (2018 - 2026) Analysis & Trends
BioNTech SE has reported Cash from Operations for 8 years, with the latest figure at 360271467.8 in Q4 2025.
- Quarterly Cash from Operations rose 172.77% year-over-year to 360271467.8 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 617578689.96 (up 192.86% YoY) and the FY2025 annual result came in at 515193902.59, up 132.12% from the prior year.
- Cash from Operations slipped to 360271467.8 in Q4 2025 per BNTX's latest filing, from 912681309.82 in the prior quarter.
- Over five years, Cash from Operations peaked at 4818442194.59 in Q3 2022 and troughed at 821206181.94 in Q1 2025.
- A 5-year average of 1159382522.17 and a median of 603130291.55 in 2022 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2024: Cash from Operations surged 1210566204.64% in 2022, then slumped 179.46% in 2024.
- Over 5 years, Cash from Operations stood at 228222204.75 in 2021, then surged by 270.69% to 845989115.3 in 2022, then advanced by 8.22% to 915517268.55 in 2023, then slumped by 154.08% to 495080248.9 in 2024, then jumped by 172.77% to 360271467.8 in 2025.
- According to Business Quant data, Cash from Operations over the past three periods registered 360271467.8, 912681309.82, and 165832094.29 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | BioNTech SE | 25.06 Bn | 11.41 Bn | 10.00 Mn | 12.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 12.20 Mn |
| Mar 31, 2026 | -492.88 Mn |
| Dec 31, 2025 | 360.27 Mn |
| Sep 30, 2025 | 912.68 Mn |
| Jun 30, 2025 | 165.83 Mn |
| Mar 31, 2025 | -821.21 Mn |
| Dec 31, 2024 | -495.08 Mn |
| Sep 30, 2024 | -701.65 Mn |
| Jun 30, 2024 | 1.75 Bn |
| Mar 31, 2024 | -344.70 Mn |
| Dec 31, 2023 | 915.52 Mn |
| Sep 30, 2023 | 883.06 Mn |
| Jun 30, 2023 | 4.78 Bn |
| Mar 31, 2023 | -727.08 Mn |
| Dec 31, 2022 | 845.99 Mn |
| Sep 30, 2022 | 4.82 Bn |
| Jun 30, 2022 | 4.18 Bn |
| Mar 31, 2022 | 4.55 Bn |
| Dec 31, 2021 | 228.22 Mn |
| Sep 30, 2021 | 1.77 Bn |